Sistema de Información Esencial en Terapéutica y Salud


Última actualización: 13/1/2021
SIETES contiene 93213 citas

 1 a 20 de 612 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Krause PR, Fleming TR, Ellenberg SS, Henao-Restrepo AM, on behalf of the WHO Ad Hoc Clinical Trial Expert Group. Maintaining confidentiality of emerging results in COVID-19 vaccine trials is essential. Lancet 2020;396:21 de noviembre. [Ref.ID 103763]
2.Enlace a cita original Cita con resumen
Podolsky SH, Herzberg D, Greene JA. Preying on prescribers (and their patients) — Pharmaceutical marketing, iatrogenic epidemics, and the Sackler legacy. N Engl J Med 2019:10 de abril. [Ref.ID 103090]
7. Cita con resumen
Habibi R, Lexchin J, Mintzes B, Holbrook A. Unwarranted claims of drug efficacy in pharmaceutical sales visits: are drugs approved on the basis of surrogate outcomes promoted appropriately?. Br J Clin Pharmacol 2017;83:2549-56. [Ref.ID 102116]
8.Tiene citas relacionadas Cita con resumen
Godlee F, Abbasi K, Bloom T. BMJ declares its revenues from industry. BMJ 2017;359:j4930. [Ref.ID 102109]
9. Cita con resumen
Greenway T, Ross JS. US drug marketing: how does promotion correspond with health value?. BMJ 2017;357:j1855. [Ref.ID 101571]
11. Cita con resumen
Fleischman W, Agrawal S, King M, Venkatesh AK, Krumholz HM, McKee D, Brown D, Ross JS. Association between payments from manufacturers of pharmaceuticals to physicians and regional prescribing: cross sectional ecological study. BMJ 2016;354:i4189. [Ref.ID 100605]
12.Enlace a cita original Cita con resumen
Anónimo. La falsa transparencia y el lavado de cara de la industria farmacéutica. NoGracias 2016:1 de julio. [Ref.ID 100507]
13. Cita con resumen
Gulland A. MSF accuses Pfizer of misleading advertising. BMJ 2016;352:i896. [Ref.ID 100060]
14. Cita con resumen
Anónimo. Drug problems: dangerous decision-making at the FDA. POGO. Project on Government Oversight 2015:15 de octubre. [Ref.ID 99569]
15. Cita con resumen
Chinthapalli K. The billion dollar business of being smart. BMJ 2015;351:h4829. [Ref.ID 99542]
16. Cita con resumen
Avorn J, Sarpatwari A, Kesselheim AS. Forbidden and permitted statements about medications - Loosening the rules. N Engl J Med 2015;373:967-73. [Ref.ID 99432]
17. Cita con resumen
Roehr B. Court rules that FDA cannot restrict off-label marketing. BMJ 2015;351:h4367. [Ref.ID 99403]
18. Cita con resumen
19. Cita con resumen
Ornstein C, Jones RG. Vying for market share, companies heavily promote ‘me too’ drugs. ProPublica 2015:7 de enero. [Ref.ID 98702]
Seleccionar todas
 1 a 20 de 612 siguiente >>